The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Drugs & Targets

Caris Life Sciences partners with Debiopharm International SA

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Caris Life Sciences announced a partnership with Debiopharm International SA for the development of a companion diagnostic test using MI Transcriptome, a Whole Transcriptome Sequencing assay for mRNA analysis.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

Dana-Farber/Harvard Cancer Center awarded $12M NIH SPORE grant to advance breast cancer research

From right to left: Geoffrey Shapiro, Leif Ellisen and Nancy Lin. Sitting below them is Kornelia Polyak.The Dana-Farber/Harvard Cancer Center,  a cancer research consortium comprised of five of Boston’s academic medical centers, including Dana-Farber Cancer Institute and Massachusetts General Hospital, has been awarded an NCI grant to continue its Specialized Program of Research Excellence in Breast Cancer.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account